Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | PALB2 del |
Gene Variant Detail | |
Relevant Treatment Approaches | PARP Inhibitor (Pan) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 del PALB2 mut | prostate cancer | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a Phase II study (TOPARP-A), a patient with metastatic castration-resistant prostate cancer harboring a frameshift PALB2 mutation together with a heterozygous PALB2 deletion achieved a response to Lynparza (olaparib) that lasted for 39 weeks (PMID: 26510020; NCT01682772). | 26510020 |